Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Truist Securities upgraded Gilead Sciences (NASDAQ:GILD), a prominent player in the biotechnology industry with a market capitalization of $137 billion, from Hold to Buy on Friday, raising its price target to $127.00 from $108.00 following the company’s strong second-quarter performance. The company maintains a "GREAT" financial health score according to InvestingPro analysis.
The upgrade comes after Gilead beat second-quarter 2025 expectations for both sales and earnings per share, with the HIV segment driving the outperformance. With impressive gross margins of 78% and a stellar 50% return over the past year, the strength in HIV prompted management to raise its full-year guidance, now projecting 3% year-over-year growth compared to its previous flat outlook.
While Gilead’s recently launched drug Yeztugo was too new to significantly impact second-quarter results, Truist Securities expressed encouragement about early demand indicators. The firm described Gilead as having "the best-in-class, unparalleled HIV business in the sector." InvestingPro subscribers can access 10+ additional exclusive insights and a comprehensive Pro Research Report about Gilead’s market position and growth potential.
Truist also highlighted that Gilead’s cancer drug Trodelvy returned to growth this quarter, increasing 14% year-over-year. The firm expressed optimism about Trodelvy’s potential frontline uptake in 2026.
Despite ongoing challenges in Gilead’s cell therapy business, Truist believes it will be reinvigorated with the addition of Anito-cel to the company’s portfolio. Based on InvestingPro’s Fair Value analysis, Gilead currently appears to be trading near its fair value, with 9 analysts recently revising their earnings estimates upward for the upcoming period.
In other recent news, Gilead Sciences announced its second-quarter 2025 earnings, surpassing Wall Street expectations. The company reported non-GAAP earnings per share of $2.01, exceeding the consensus estimate of $1.98. Additionally, Gilead’s revenue reached $7.1 billion, surpassing the anticipated $6.97 billion. UBS responded to these results by raising its price target for Gilead Sciences from $108 to $112, while maintaining a Neutral rating on the stock. The increase in the price target reflects the company’s strong financial performance. These developments indicate a positive reaction from the market and analysts to Gilead’s recent financial results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.